ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CCCC / insiders
EDIT (29) ALLO (33) AUTL (21) PROK (35) ⌘ Pro Terminal →

C4 Therapeutics Inc. (CCCC) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.21 -4.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.18

C4 Therapeutics Inc. (CCCC) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $414.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CCCC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CCCC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, C4 Therapeutics Inc. (NASDAQ: CCCC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $3.21 (-4.75% 1D, market cap $414.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CCCC ranks #827 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CCCC compare to EDIT and ALLO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CCCC carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EDIT (Editas Medicine Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $410.1M) and ALLO (Allogene Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $407.7M). Among the 5-stock peer group, CCCC leads on earnings multiple (N/A) while CCCC leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CCCC?
▼

Per CCCC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001662579), C4 Therapeutics Inc. generated $35.9M in revenue (+1.0% YoY), -$105.0M in net income, and -$99.3M in free cash flow against $359.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.18 (-1.04%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (12)SEC (5)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.1% Base Target
$5 Bull$3 Base$2 Bear
📬 FREE CCCC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CCCC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY CCCC SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (41% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (24% of score)

FRED Regime × Technicals: 44% of 52W Range • RSI-14 at 56.6 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
21
Grade E$2.78+13.7% Next Q
Q2 (-2Q)
24
Grade E$3.16+1.6% Next Q
Q3 (-1Q)
26
Grade E$3.21+0% Next Q
Current
29
Grade E$3.21-9.8% Hist 90D α
Trajectory: E (21) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CCCC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CCCC currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.29) and Max Pain ($3.37) forces dealer call-delta covering toward $5.43.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CCCC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CCCC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CCCC Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CCCC)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CCCC. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CCCC)

  • ✓Walkthrough of CCCC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CCCC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.59%▼ DESCENDING CHANNEL
2026-11-03O $3.30H $3.37L $3.21C $3.21VOL 2.35M
RES: $3.46SUP: $2.38SMA50: $3.29SMA200: $3.22
$5.36$4.57$3.79$3.00$2.22RES $3.46SUP $2.38$3.212026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CCCC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CCCC Butterfly Map → + Track CCCC →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +1.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CCCC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CCCC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CCCC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CCCC)

Health Care Rank #827 of 1015 ⚔️ EDIT vs CCCC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CCCC vs. EDIT, ALLO, AUTL, PROK)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, C4 Therapeutics Inc. (CCCC) ranks #827 by composite RQD confidence (29/100, grade E) and #467 by equity capitalization ($414.6M). Within this direct 5-issuer industry benchmark cohort, CCCC leads on earnings valuation at N/A trailing P/E, while CCCC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PROK currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with CCCC at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CCCC ACTIVE
C4 Therapeutics Inc.
E 29/100 — — -35.0% -4.75% $414.6M Benchmark Subject
EDIT
Editas Medicine Inc.
E 29/100 — — -35.0% -3.74% $410.1M /edit-vs-cccc →
ALLO
Allogene Therapeutics Inc.
E 33/100 — — -35.0% -7.63% $407.7M /allo-vs-cccc →
AUTL
Autolus Therapeutics plc
E 21/100 — -27.8% -35.0% -6.58% $404.6M /autl-vs-cccc →
PROK
ProKidney Corp. (Class A)
D- 35/100 — — -35.0% -13.51% $391.6M /prok-vs-cccc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001662579 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), C4 Therapeutics Inc. (CCCC) reported GAAP revenue of $35.9M (+1.0% vs. FY2024 revenue of $35.6M , and +73.2% cumulative change since FY2023) , GAAP net income of -$105.0M, operating cash flow of -$98.7M, and free cash flow of -$99.3M (-52.0% YoY). On the balance sheet, CCCC closed FY2025 with $359.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $35.9M -$105.0M -$98.7M -$99.3M $359.1M —
FY2024 (FY) 2024-12-31 $35.6M -$105.3M -$65.2M -$65.3M $349.6M —
FY2023 (FY) 2023-12-31 $20.8M -$132.5M -$106.8M -$106.8M — —

3. CCCC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CCCC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, C4 Therapeutics Inc. (NASDAQ: CCCC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $3.21 (-4.75% 1D, market cap $414.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CCCC ranks #827 in composite RQD confidence.

How does CCCC compare to EDIT and ALLO in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CCCC carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EDIT (Editas Medicine Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $410.1M) and ALLO (Allogene Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $407.7M). Among the 5-stock peer group, CCCC leads on earnings multiple (N/A) while CCCC leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CCCC?

Per CCCC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001662579), C4 Therapeutics Inc. generated $35.9M in revenue (+1.0% YoY), -$105.0M in net income, and -$99.3M in free cash flow against $359.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CCCC trading relative to its 50-day, 200-day, and 52-week technical levels?

CCCC last traded at $3.21 (-4.75% on volume of 2,861,882 shares), positioning the stock -2.43% below its 50-day simple moving average ($3.29) and -0.31% below its 200-day simple moving average ($3.22). Across its 52-week range of $1.69 to $5.17, CCCC sits at the 43.7% percentile with a 14-day RSI of 56.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.81 to $3.61).

Direct Sub-Reports: CCCC RQD Cockpit CCCC 12M Forecast CCCC Earnings & Move CCCC Dividends & DRIP CCCC Insiders & 13F CCCC Whale Options CCCC Profit Sankey CCCC News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

CCCC — C4 Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

C4 Therapeutics Inc. (CCCC) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.21 (-4.75% 1D, market capitalization $414.6M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -24.46%.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

C4 Therapeutics Inc. (CCCC) is listed on NASDAQ and operates in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The market capitalization is $0.4B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), C4 Therapeutics Inc. (CCCC) reported $35.9M in annual revenue (up from $35.6M in FY2024, +1.0% YoY) and -$105.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($20.8M revenue, -$132.5M net income) through FY2025, CCCC scaled operating cash flow to -$98.7M and free cash flow to -$99.3M, backed by $359.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -24.46% and institutional whale pillar of 12/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $1.69 – $5.17 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The sector and industry classification is the only sector context provided.

  • Key Question #1: Can CCCC sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $35.9M and free cash flow of -$99.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CCCC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CCCC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for C4 Therapeutics Inc. (CCCC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CCCC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CCCC Bull vs. Bear Conversation Board — What's Your Call at $3.21?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CCCC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CCCC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $4.18 (+24.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 10/20 and a JPMorgan Overweight initiation is in the news feed.

Here is why I am bullish on CCCC here at $3.37: Institutional accumulation and options positioning score 10/20 and a JPMorgan Overweight initiation is in the news feed.. Compare CCCC's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $3.20 are getting bought.

RetailWhale_TX 🐂 BULL

Both sides have a point here — CCCC's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $2.90 (-13.9%)
Spot @ $3.37

ROIC of -35%, FCF yield of -24.46%, and an Altman Z-Score of 0.2 place the company in the weakest fundamental and forensic zones of the

I respect the product at C4 Therapeutics Inc., but the stock at $3.37 is a different story. ROIC of -35%, FCF yield of -24.46%, and an Altman Z-Score of 0.2 place the company in the weakest fundamental and forensic zones of the RQD rating.. FCF yield is -24.46% and RQD sits at 29/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%